Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cybin Inc (CLXPF)

Cybin Inc (CLXPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 453,224
  • Shares Outstanding, K 148,598
  • Annual Sales, $ 650 K
  • Annual Income, $ -24,420 K
  • 60-Month Beta N/A
  • Price/Sales 603.54
  • Price/Cash Flow N/A
  • Price/Book 6.79
Trade CLXPF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.1105 +43.09%
on 07/08/21
3.3800 -10.65%
on 08/02/21
+0.9000 (+42.45%)
since 07/02/21
3-Month
1.3429 +124.89%
on 06/01/21
3.3800 -10.65%
on 08/02/21
+1.3400 (+79.76%)
since 05/04/21

Most Recent Stories

More News
Psychedelics Could Positively Impact the $2.5 Trillion Mental Health Market

Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release, “The surge...

CYBN : 9.68 (-1.43%)
CLXPF : 3.0200 (-1.31%)
FTRP.TO : 1.09 (+5.83%)
FTRP : 4.2105 (+1.07%)
MCUR.CN : 0.075 (+36.36%)
MCURF : 0.5070 (+148.53%)
ATAI : 1.0900 (-0.91%)
NEON.CN : 0.300 (unch)
NMDBF : 0.0076 (+11.76%)
Psychedelics Could Alter a Potential $2.5 Trillion Mental Health Market

Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to ...

CYBN : 9.68 (-1.43%)
CLXPF : 3.0200 (-1.31%)
FTRP.TO : 1.09 (+5.83%)
FTRP : 4.2105 (+1.07%)
MCURF : 0.5070 (+148.53%)
ATAI : 1.0900 (-0.91%)
NMDBF : 0.0076 (+11.76%)
FTRP.CN : 5.550 (+1.46%)
MCUR.CN : 0.075 (+36.36%)
NEON.CN : 0.300 (unch)
Cybin to Commence Trading on the NYSE American on August 5

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open...

CYBN.NE : 13.3400 (-0.45%)
CLXPF : 3.0200 (-1.31%)
Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for...

CYBN.NE : 13.3400 (-0.45%)
CLXPF : 3.0200 (-1.31%)
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced...

CYBN.NE : 13.3400 (-0.45%)
CYBN : 9.68 (-1.43%)
CLXPF : 3.0200 (-1.31%)
Cybin Announces Conditional Listing Approval from NYSE American

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional...

CYBN.NE : 13.3400 (-0.45%)
CLXPF : 3.0200 (-1.31%)
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional...

CYBN.NE : 13.3400 (-0.45%)
CLXPF : 3.0200 (-1.31%)
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive...

CYBN.NE : 13.3400 (-0.45%)
CLXPF : 3.0200 (-1.31%)
Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations...

CYBN.NE : 13.3400 (-0.45%)
CLXPF : 3.0200 (-1.31%)
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market

Palm Beach, FL – July 7, 2021 – Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of...

CYBN.NE : 13.3400 (-0.45%)
OPTI.CN : 0.2250 (-2.17%)
OPTHF : 0.1702 (+6.38%)
MNMD : 5.91 (+1.81%)
CMPS : 5.94 (-2.94%)
ATAI : 1.0900 (-0.91%)
CLXPF : 3.0200 (-1.31%)
CYBN : 9.68 (-1.43%)
GTMS.TO : 0.97 (-15.65%)
GBNH : 0.1210 (-40.69%)

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 3.5152
2nd Resistance Point 3.3576
1st Resistance Point 3.1888
Last Price 3.0200
1st Support Level 2.8624
2nd Support Level 2.7048
3rd Support Level 2.5360

See More

52-Week High 3.3800
Last Price 3.0200
Fibonacci 61.8% 2.2775
Fibonacci 50% 1.9369
Fibonacci 38.2% 1.5963
52-Week Low 0.4938

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar